Nonproliferative Diabetic Retinopathy and Diabetic Macular Edema

Retina Fifth Edition

Volumn 2, Issue , 2012, Pages 940-968

  Wiley, Henry E ^a   Ferris III, Frederick L ^a  

^a NATIONAL EYE INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84906798848     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4557-0737-9.00047-3     Document Type: Chapter

References (228)

1. Cogan DG, Toussaint D, Kuwabara T Retinal vascular patterns. IV. Diabetic retinopathy. Arch Ophthalmol 1961, 66:366-378.
2. Cogan DG, Kuwabara T Capillary shunts in the pathogenesis of diabetic retinopathy. Diabetes 1963, 12:293-300.
3. Kuwabara T, Cogan DG Retinal vascular patterns. VI. Mural cells of the retinal capillaries. Arch Ophthalmol 1963, 69:492-502.
4. Toussaint D, Dustin P Electron microscopy of normal and diabetic retinal capillaries. Arch Ophthalmol 1963, 70:96-108.
5. Speiser P, Gittelsohn AM, Patz A Studies on diabetic retinopathy. 3. Influence of diabetes on intramural pericytes. Arch Ophthalmol 1968, 80:332-337.
6. Babel J, Leuenberger P A long term study on the ocular lesions in streptozotocin diabetic rats. Albrecht Von Graefes Arch Klin Exp Ophthalmol 1974, 189:191-209.
7. Robison WG, Kador PF, Kinoshita JH Retinal capillaries: basement membrane thickening by galactosemia prevented with aldose reductase inhibitor. Science 1983, 221:1177-1179.
8. Sima AA, Garcia-Salinas R, Basu PK The BB Wistar rat: an experimental model for the study of diabetic retinopathy. Metabolism 1983, 32:136-140.
9. Engerman RL, Kern TS Experimental galactosemia produces diabetic-like retinopathy. Diabetes 1984, 33:97-100.
10. Kozak WM, Marker NA, Elmer KK Effects of aldose reductase inhibition on the retina and health indices of streptozotocin-diabetic rats. Doc Ophthalmol 1986, 64:355-377.
11. Kador PF, Akagi Y, Terubayashi H, et al. Prevention of pericyte ghost formation in retinal capillaries of galactose-fed dogs by aldose reductase inhibitors. Arch Ophthalmol 1988, 106:1099-1102.
12. Kador PF, Akagi Y, Takahashi Y, et al. Prevention of retinal vessel changes associated with diabetic retinopathy in galactose-fed dogs by aldose reductase inhibitors. Arch Ophthalmol 1990, 108:1301-1309.
13. Takahashi Y, Wyman M, Ferris F, et al. Diabeteslike preproliferative retinal changes in galactose-fed dogs. Arch Ophthalmol 1992, 110:1295-1302.
14. Kern TS, Engerman RL Comparison of retinal lesions in alloxan-diabetic rats and galactose-fed rats. Curr Eye Res 1994, 13:863-867.
15. Engerman RL, Kern TS Retinopathy in animal models of diabetes. Diabetes Metab Rev 1995, 11:109-120.
16. Kador PF, Takahashi Y, Wyman M, et al. Diabeteslike proliferative retinal changes in galactose-fed dogs. Arch Ophthalmol 1995, 113:352-354.
17. Kern TS, Engerman RL Galactose-induced retinal microangiopathy in rats. Invest Ophthalmol Vis Sci 1995, 36:490-496.
18. Robison WG Diabetic retinopathy: galactose-fed rat model. Invest Ophthalmol Vis Sci 1995, 36:1743-1744. 4A.
19. Kobayashi T, Kubo E, Takahashi Y, et al. Retinal vessel changes in galactose-fed dogs. Arch Ophthalmol 1998, 116:785-789.
20. Kador PF, Takahashi Y, Akagi Y, et al. Age-dependent retinal capillary pericyte degeneration in galactose-fed dogs. J Ocul Pharmacol Ther 2007, 23:63-69.
21. Roy S, Ha J, Trudeau K, et al. Vascular basement membrane thickening in diabetic retinopathy. Curr Eye Res 2010, 35:1045-1056.
22. Barber AJ A new view of diabetic retinopathy: a neurodegenerative disease of the eye. Prog Neuropsychopharmacol Biol Psychiatry 2003, 27:283-290.
23. Barber AJ, Lieth E, Khin SA, et al. Neural apoptosis in the retina during experimental and human diabetes. Early onset and effect of insulin. J Clin Invest 1998, 102:783-791.
24. Lieth E, Barber AJ, Xu B, et al. Glial reactivity and impaired glutamate metabolism in short-term experimental diabetic retinopathy. Penn State Retina Research Group. Diabetes 1998, 47:815-820.
25. Lieth E, Gardner TW, Barber AJ, et al. Retinal neurodegeneration: early pathology in diabetes. Clin Experiment Ophthalmol 2000, 28:3-8.
26. Martin PM, Roon P, Van Ells TK, et al. Death of retinal neurons in streptozotocin-induced diabetic mice. Invest Ophthalmol Vis Sci 2004, 45:3330-3336.
27. Mizutani M, Gerhardinger C, Lorenzi M Muller cell changes in human diabetic retinopathy. Diabetes 1998, 47:445-449.
28. Whitmire W, Al-Gayyar MM, Abdelsaid M, et al. Alteration of growth factors and neuronal death in diabetic retinopathy: what we have learned so far. Mol Vis 2011, 17:300-308.
29. Della Sala S, Bertoni G, Somazzi L, et al. Impaired contrast sensitivity in diabetic patients with and without retinopathy: a new technique for rapid assessment. Br J Ophthalmol 1985, 69:136-142.
30. Greenstein V, Sarter B, Hood D, et al. Hue discrimination and S cone pathway sensitivity in early diabetic retinopathy. Invest Ophthalmol Vis Sci 1990, 31:1008-1014.
31. Kurtenbach A, Wagner U, Neu A, et al. Brightness matching and colour discrimination in young diabetics without retinopathy. Vision Res 1994, 34:115-122.
32. Sokol S, Moskowitz A, Skarf B, et al. Contrast sensitivity in diabetics with and without background retinopathy. Arch Ophthalmol 1985, 103:51-54.
33. Tregear SJ, Knowles PJ, Ripley LG, et al. Chromatic-contrast threshold impairment in diabetes. Eye (Lond) 1997, 11(Pt 4):537-546.
34. Trick GL, Burde RM, Gordon MO, et al. The relationship between hue discrimination and contrast sensitivity deficits in patients with diabetes mellitus. Ophthalmology 1988, 95:693-698.
35. Klein R, Meuer SM, Moss SE, et al. The relationship of retinal microaneurysm counts to the 4-year progression of diabetic retinopathy. Arch Ophthalmol 1989, 107:1780-1785.
36. Klein R, Meuer SM, Moss SE, et al. Retinal microaneurysm counts and 10-year progression of diabetic retinopathy. Arch Ophthalmol 1995, 113:1386-1391.
37. Kohner EM, Sleightholm M Does microaneurysm count reflect severity of early diabetic retinopathy?. Ophthalmology 1986, 93:586-589.
38. Early Treatment Diabetic Retinopathy Study Research Group Photocoagulation for diabetic macular edema. Early Treatment Diabetic Retinopathy Study report number 1. Arch Ophthalmol 1985, 103:1796-1806.
39. Kohner EM, Henkind P Correlation of fluorescein angiogram and retinal digest in diabetic retinopathy. Am J Ophthalmol 1970, 69:403-414.
40. Adamis AP, Miller JW, Bernal MT, et al. Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol 1994, 118:445-450.
41. Aiello LP, Avery RL, Arrigg PG, et al. Vascular endothelial growth factor in ocular fluid of patients with diabetic retinopathy and other retinal disorders. N Engl J Med 1994, 331:1480-1487.
42. Aiello LP, Northrup JM, Keyt BA, et al. Hypoxic regulation of vascular endothelial growth factor in retinal cells. Arch Ophthalmol 1995, 113:1538-1544.
43. Miller JW, Adamis AP, Shima DT, et al. Vascular endothelial growth factor/vascular permeability factor is temporally and spatially correlated with ocular angiogenesis in a primate model. Am J Pathol 1994, 145:574-584.
44. Pe'er J, Shweiki D, Itin A, et al. Hypoxia-induced expression of vascular endothelial growth factor by retinal cells is a common factor in neovascularizing ocular diseases. Lab Invest 1995, 72:638-645.
45. Shweiki D, Itin A, Soffer D, et al. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1992, 359:843-845.
46. Adamis AP, Shima DT, Tolentino MJ, et al. Inhibition of vascular endothelial growth factor prevents retinal ischemia-associated iris neovascularization in a nonhuman primate. Arch Ophthalmol 1996, 114:66-71.
47. Robinson GS, Pierce EA, Rook SL, et al. Oligodeoxynucleotides inhibit retinal neovascularization in a murine model of proliferative retinopathy. Proc Natl Acad Sci U S A 1996, 93:4851-4856.
48. Fraser-Bell S, Ying-Lai M, Klein R, et al. Prevalence and associations of epiretinal membranes in Latinos: the Los Angeles Latino Eye Study. Invest Ophthalmol Vis Sci 2004, 45:1732-1736.
49. Kawasaki R, Wang JJ, Sato H, et al. Prevalence and associations of epiretinal membranes in an adult Japanese population: the Funagata study. Eye (Lond) 2009, 23:1045-1051.
50. Klein R, Klein BE, Wang Q, et al. The epidemiology of epiretinal membranes. Trans Am Ophthalmol Soc 1994, 92:403-425. discussion 25-30.
51. Mitchell P, Smith W, Chey T, et al. Prevalence and associations of epiretinal membranes. The Blue Mountains Eye Study, Australia. Ophthalmology 1997, 104:1033-1040.
52. Ng CH, Cheung N, Wang JJ, et al. Prevalence and risk factors for epiretinal membranes in a multi-ethnic United States population. Ophthalmology 2011, 118:694-699.
53. Sebag J Anomalous posterior vitreous detachment: a unifying concept in vitreo-retinal disease. Graefes Arch Clin Exp Ophthalmol 2004, 242:690-698.
54. Barile GR, Pachydaki SI, Tari SR, et al. The RAGE axis in early diabetic retinopathy. Invest Ophthalmol Vis Sci 2005, 46:2916-2924.
55. Gao BB, Chen X, Timothy N, et al. Characterization of the vitreous proteome in diabetes without diabetic retinopathy and diabetes with proliferative diabetic retinopathy. J Proteome Res 2008, 7:2516-2525.
56. Kim T, Kim SJ, Kim K, et al. Profiling of vitreous proteomes from proliferative diabetic retinopathy and nondiabetic patients. Proteomics 2007, 7:4203-4215.
57. Sebag J, Buckingham B, Charles MA, et al. Biochemical abnormalities in vitreous of humans with proliferative diabetic retinopathy. Arch Ophthalmol 1992, 110:1472-1476.
58. Shitama T, Hayashi H, Noge S, et al. Proteome profiling of vitreoretinal diseases by cluster analysis. Proteomics Clin Appl 2008, 2:1265-1280.
59. Holekamp NM The vitreous gel: more than meets the eye. Am J Ophthalmol 2010, 149:32-36.
60. Shui YB, Holekamp NM, Kramer BC, et al. The gel state of the vitreous and ascorbate-dependent oxygen consumption: relationship to the etiology of nuclear cataracts. Arch Ophthalmol 2009, 127:475-482.
61. Chen MS, Kao CS, Chang CJ, et al. Prevalence and risk factors of diabetic retinopathy among noninsulin-dependent diabetic subjects. Am J Ophthalmol 1992, 114:723-730.
62. Cikamatana L, Mitchell P, Rochtchina E, et al. Five-year incidence and progression of diabetic retinopathy in a defined older population: the Blue Mountains Eye Study. Eye (Lond) 2007, 21:465-471.
63. Klein R, Klein BE, Moss SE, et al. The Wisconsin Epidemiologic Study of diabetic retinopathy. XIV. Ten-year incidence and progression of diabetic retinopathy. Arch Ophthalmol 1994, 112:1217-1228.
64. Klein R, Klein BE, Moss SE, et al. The Wisconsin Epidemiologic Study of diabetic retinopathy. III. Prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more years. Arch Ophthalmol 1984, 102:527-532.
65. Klein R, Klein BE, Moss SE, et al. The Wisconsin Epidemiologic Sstudy of diabetic retinopathy. II. Prevalence and risk of diabetic retinopathy when age at diagnosis is less than 30 years. Arch Ophthalmol 1984, 102:520-526.
66. Leske MC, Wu SY, Hennis A, et al. Hyperglycemia, blood pressure, and the 9-year incidence of diabetic retinopathy: the Barbados Eye Studies. Ophthalmology 2005, 112:799-805.
67. Svensson M, Eriksson JW, Dahlquist G Early glycemic control, age at onset, and development of microvascular complications in childhood-onset type 1 diabetes: a population-based study in northern Sweden. Diabetes Care 2004, 27:955-962.
68. Varma R, Choudhury F, Klein R, et al. Four-year incidence and progression of diabetic retinopathy and macular edema: the Los Angeles Latino Eye Study. Am J Ophthalmol 2010, 149:752-761. 3.
69. Wong TY, Cheung N, Tay WT, et al. Prevalence and risk factors for diabetic retinopathy: the Singapore Malay Eye Study. Ophthalmology 2008, 115:1869-1875.
70. Zhang X, Saaddine JB, Chou CF, et al. Prevalence of diabetic retinopathy in the United States, 2005-2008. JAMA 2010, 304:649-656.
71. Centers for Disease Control and Prevention [Internet]. Atlanta, GA: CDC [update 2011 May 23; cited 2012 Feb 2]. National Diabetes Fact Sheet: Diagnosed and undiagnosed diabetes in the United States, all ages, Available from. http://www.cdc.gov/diabetes/pubs/estimates11.htm#1.
72. The Diabetes Control and Complications Trial Research Group The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med 1993, 329:977-986.
73. Diabetes Control and Complications Trial Research Group The relationship of glycemic exposure (HbA1c) to the risk of development and progression of retinopathy in the diabetes control and complications trial. Diabetes 1995, 44:968-983.
74. UK Prospective Diabetes Study (UKPDS) Group Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet 1998, 352:837-853.
75. UK Prospective Diabetes Study (UKPDS) Group Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998, 352:854-865.
76. The Diabetes Control and Complications Trial/Epidemiology of Diabetes Intervention and Complications Study Research Group Effect of intensive therapy on the microvascular complications of type 1 diabetes mellitus. JAMA 2002, 287:2563-2569.
77. Holman RR, Paul SK, Bethel MA, et al. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008, 359:1577-1589.
78. Chew EY, Ambrosius WT, Davis MD, et al. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med 2010, 363:233-244.
79. The effect of intensive diabetes treatment on the progression of diabetic retinopathy in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial. Arch Ophthalmol 1995, 113:36-51.
80. UK Prospective Diabetes Study Group Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998, 317:703-713.
81. Klein BE, Moss SE, Klein R, et al. The Wisconsin Epidemiologic Study of Diabetic Retinopathy. XIII. Relationship of serum cholesterol to retinopathy and hard exudate. Ophthalmology 1991, 98:1261-1265.
82. Chew EY, Klein ML, Ferris FL, et al. Association of elevated serum lipid levels with retinal hard exudate in diabetic retinopathy. Early Treatment Diabetic Retinopathy Study (ETDRS) Report 22. Arch Ophthalmol 1996, 114:1079-1084.
83. Davis MD, Fisher MR, Gangnon RE, et al. Risk factors for high-risk proliferative diabetic retinopathy and severe visual loss: Early Treatment Diabetic Retinopathy Study Report #18. Invest Ophthalmol Vis Sci 1998, 39:233-252.
84. Keech AC, Mitchell P, Summanen PA, et al. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. Lancet 2007, 370:1687-1697.
85. Janka HU, Warram JH, Rand LI, et al. Risk factors for progression of background retinopathy in long-standing IDDM. Diabetes 1989, 38:460-464.
86. Rand LI, Prud'homme GJ, Ederer F, et al. Factors influencing the development of visual loss in advanced diabetic retinopathy. Diabetic Retinopathy Study (DRS) Report No. 10. Invest Ophthalmol Vis Sci 1985, 26:983-991.
87. Berman DH, Friedman EA Partial absorption of hard exudates in patients with diabetic end-stage renal disease and severe anemia after treatment with erythropoietin. Retina 1994, 14:1-5.
88. Qiao Q, Keinanen-Kiukaanniemi S, Laara E The relationship between hemoglobin levels and diabetic retinopathy. J Clin Epidemiol 1997, 50:153-158.
89. Shorb SR Anemia and diabetic retinopathy. Am J Ophthalmol 1985, 100:434-436.
90. Krolewski AS, Barzilay J, Warram JH, et al. Risk of early-onset proliferative retinopathy in IDDM is closely related to cardiovascular autonomic neuropathy. Diabetes 1992, 41:430-437.
91. Tesfaye S, Stevens LK, Stephenson JM, et al. Prevalence of diabetic peripheral neuropathy and its relation to glycaemic control and potential risk factors: the EURODIAB IDDM Complications Study. Diabetologia 1996, 39:1377-1384.
92. American Academy of Ophthalmology [homepage on the Internet] San Francisco, CA: AAO; 2008 [cited 2012 Feb 2]. American Academy of Ophthalmology Retina Panel. Preferred Practice Pattern® guidelines. Diabetic retinopathy. Available from. http://www.aao.org/ppp.
93. Klein R, Klein BE, Neider MW, et al. Diabetic retinopathy as detected using ophthalmoscopy, a nonmydriatic camera and a standard fundus camera. Ophthalmology 1985, 92:485-491.
94. Yannuzzi LA, Rohrer KT, Tindel LJ, et al. Fluorescein angiography complication survey. Ophthalmology 1986, 93:611-617.
95. AK-FLUOR (fluorescein sodium) injection for intravenous use. Full prescribing information. Package insert. Revised 7/2008.
96. Diabetic Retinopathy Clinical Research Network [homepage on the Internet] 2007-12 [cited 2012 Feb 2]. Available from. http://drcrnet.jaeb.org/.
97. Bressler NM, Edwards AR, Antoszyk AN, et al. Retinal thickness on Stratus optical coherence tomography in people with diabetes and minimal or no diabetic retinopathy. Am J Ophthalmol 2008, 145:894-901.
98. Krzystolik MG, Strauber SF, Aiello LP, et al. Reproducibility of macular thickness and volume using Zeiss optical coherence tomography in patients with diabetic macular edema. Ophthalmology 2007, 114:1520-1525.
99. Forooghian F, Cukras C, Meyerle CB, et al. Evaluation of time domain and spectral domain optical coherence tomography in the measurement of diabetic macular edema. Invest Ophthalmol Vis Sci 2008, 49:4290-4296.
100. Diabetic Retinopathy Study Research Group A modification of the Airlie House classification of diabetic retinopathy. Report Number 7. Invest Ophthalmol Vis Sci 1981, 21:210-226.
101. Grading diabetic retinopathy from stereoscopic color fundus photographs - an extension of the modified Airlie House classification ETDRS report number 10. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology 1991, 98:786-806.
102. Fundus photographic risk factors for progression of diabetic retinopathy ETDRS report number 12. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology 1991, 98:823-833.
103. Early photocoagulation for diabetic retinopathy ETDRS report number 9. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology 1991, 98:766-785.
104. Klein R, Klein BE, Moss SE How many steps of progression of diabetic retinopathy are meaningful? The Wisconsin Epidemiologic Study of diabetic retinopathy. Arch Ophthalmol 2001, 119:547-553.
105. Murphy RP Management of diabetic retinopathy. Am Fam Physician 1995, 51:785-796.
106. Wilkinson CP, Ferris FL, Klein RE, et al. Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. Ophthalmology 2003, 110:1677-1682.
107. Brown JC, Solomon SD, Bressler SB, et al. Detection of diabetic foveal edema: contact lens biomicroscopy compared with optical coherence tomography. Arch Ophthalmol 2004, 122:330-335.
108. Davis MD, Bressler SB, Aiello LP, et al. Comparison of time-domain OCT and fundus photographic assessments of retinal thickening in eyes with diabetic macular edema. Invest Ophthalmol Vis Sci 2008, 49:1745-1752.
109. Browning DJ, Glassman AR, Aiello LP, et al. Optical coherence tomography measurements and analysis methods in optical coherence tomography studies of diabetic macular edema. Ophthalmology 2008, 115:1366-1371. 71 e1.
110. Fluorescein angiographic risk factors for progression of diabetic retinopathy ETDRS report number 13. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology 1991, 98:834-840.
111. Danis RP, Scott IU, Qin H, et al. Association of fluorescein angiographic features with visual acuity and with optical coherence tomographic and stereoscopic color fundus photographic features of diabetic macular edema in a randomized clinical trial. Retina 2010, 30:1627-1637.
112. Neubauer AS, Chryssafis C, Priglinger SG, et al. Topography of diabetic macular oedema compared with fluorescein angiography. Acta Ophthalmol Scand 2007, 85:32-39.
113. Framme C, Roider J Immediate and long-term changes of fundus autofluorescence in continuous wave laser lesions of the retina. Ophthalmic Surg Lasers Imaging 2004, 35:131-138.
114. Muqit MM, Gray JC, Marcellino GR, et al. Fundus autofluorescence and Fourier-domain optical coherence tomography imaging of 10 and 20 millisecond Pascal retinal photocoagulation treatment. Br J Ophthalmol 2009, 93:518-525.
115. Fong DS, Segal PP, Myers F, et al. Subretinal fibrosis in diabetic macular edema. ETDRS report 23. Early Treatment Diabetic Retinopathy Study Research Group. Arch Ophthalmol 1997, 115:873-877.
116. Bandello F, Polito A, Del Borrello M, et al. "Light" versus "classic" laser treatment for clinically significant diabetic macular oedema. Br J Ophthalmol 2005, 89:864-870.
117. Catier A, Tadayoni R, Paques M, et al. Characterization of macular edema from various etiologies by optical coherence tomography. Am J Ophthalmol 2005, 140:200-206.
118. Goebel W, Kretzchmar-Gross T Retinal thickness in diabetic retinopathy: a study using optical coherence tomography (OCT). Retina 2002, 22:759-767.
119. Hee MR, Puliafito CA, Wong C, et al. Quantitative assessment of macular edema with optical coherence tomography. Arch Ophthalmol 1995, 113:1019-1029.
120. Laursen ML, Moeller F, Sander B, et al. Subthreshold micropulse diode laser treatment in diabetic macular oedema. Br J Ophthalmol 2004, 88:1173-1179.
121. Martidis A, Duker JS, Greenberg PB, et al. Intravitreal triamcinolone for refractory diabetic macular edema. Ophthalmology 2002, 109:920-927.
122. Massin P, Duguid G, Erginay A, et al. Optical coherence tomography for evaluating diabetic macular edema before and after vitrectomy. Am J Ophthalmol 2003, 135:169-177.
123. Otani T, Kishi S Tomographic findings of foveal hard exudates in diabetic macular edema. Am J Ophthalmol 2001, 131:50-54.
124. Ozdemir H, Karacorlu M, Karacorlu SA Regression of serous macular detachment after intravitreal triamcinolone acetonide in patients with diabetic macular edema. Am J Ophthalmol 2005, 140:251-255.
125. Browning DJ, Glassman AR, Aiello LP, et al. Relationship between optical coherence tomography-measured central retinal thickness and visual acuity in diabetic macular edema. Ophthalmology 2007, 114:525-536.
126. Danis RP, Glassman AR, Aiello LP, et al. Diurnal variation in retinal thickening measurement by optical coherence tomography in center-involved diabetic macular edema. Arch Ophthalmol 2006, 124:1701-1707.
127. American Diabetes Association Standards of medical care in diabetes - 2011. Diabetes Care 2011, 34(Suppl 1):S11-S61.
128. Lachin JM Point: Intensive glycemic control and mortality in ACCORD - a chance finding?. Diabetes Care 2010, 33:2719-2721.
129. Riddle MC Counterpoint: Intensive glucose control and mortality in ACCORD - still looking for clues. Diabetes Care 2010, 33:2722-2724.
130. Gerstein HC, Miller ME, Genuth S, et al. Long-term effects of intensive glucose lowering on cardiovascular outcomes. N Engl J Med 2011, 364:818-828.
131. Fong DS, Sharza M, Chen W, et al. Vision loss among diabetics in a group model Health Maintenance Organization (HMO). Am J Ophthalmol 2002, 133:236-241.
132. Kraft SK, Marrero DG, Lazaridis EN, et al. Primary care physicians' practice patterns and diabetic retinopathy. Current levels of care. Arch Fam Med 1997, 6:29-37.
133. Lee PP, Feldman ZW, Ostermann J, et al. Longitudinal rates of annual eye examinations of persons with diabetes and chronic eye diseases. Ophthalmology 2003, 110:1952-1959.
134. Paz SH, Varma R, Klein R, et al. Noncompliance with vision care guidelines in Latinos with type 2 diabetes mellitus: the Los Angeles Latino Eye Study. Ophthalmology 2006, 113:1372-1377.
135. Schoenfeld ER, Greene JM, Wu SY, et al. Patterns of adherence to diabetes vision care guidelines: baseline findings from the Diabetic Retinopathy Awareness Program. Ophthalmology 2001, 108:563-571.
136. Zimmer-Galler IE, Zeimer R Telemedicine in diabetic retinopathy screening. Int Ophthalmol Clin 2009, 49:75-86.
137. Ahmed J, Ward TP, Bursell SE, et al. The sensitivity and specificity of nonmydriatic digital stereoscopic retinal imaging in detecting diabetic retinopathy. Diabetes Care 2006, 29:2205-2209.
138. Bursell SE, Cavallerano JD, Cavallerano AA, et al. Stereo nonmydriatic digital-video color retinal imaging compared with Early Treatment Diabetic Retinopathy Study seven standard field 35-mm stereo color photos for determining level of diabetic retinopathy. Ophthalmology 2001, 108:572-585.
139. Fransen SR, Leonard-Martin TC, Feuer WJ, et al. Clinical evaluation of patients with diabetic retinopathy: accuracy of the Inoveon diabetic retinopathy-3DT system. Ophthalmology 2002, 109:595-601.
140. Lin DY, Blumenkranz MS, Brothers RJ, et al. The sensitivity and specificity of single-field nonmydriatic monochromatic digital fundus photography with remote image interpretation for diabetic retinopathy screening: a comparison with ophthalmoscopy and standardized mydriatic color photography. Am J Ophthalmol 2002, 134:204-213.
141. Schiffman RM, Jacobsen G, Nussbaum JJ, et al. Comparison of a digital retinal imaging system and seven-field stereo color fundus photography to detect diabetic retinopathy in the primary care environment. Ophthalmic Surg Lasers Imaging 2005, 36:46-56.
142. Tennant MT, Greve MD, Rudnisky CJ, et al. Identification of diabetic retinopathy by stereoscopic digital imaging via teleophthalmology: a comparison to slide film. Can J Ophthalmol 2001, 36:187-196.
143. Whited JD Accuracy and reliability of teleophthalmology for diagnosing diabetic retinopathy and macular edema: a review of the literature. Diabetes Technol Ther 2006, 8:102-111.
144. Jonas JB, Sofker A Intraocular injection of crystalline cortisone as adjunctive treatment of diabetic macular edema. Am J Ophthalmol 2001, 132:425-427.
145. Chan CK, Chan WM, Cheung BT, et al. Intravitreal injection of triamcinolone for diffuse diabetic macular edema. Arch Ophthalmol 2004, 122:1083-1085. author reply 6-8.
146. Ip MS Intravitreal injection of triamcinolone: an emerging treatment for diabetic macular edema. Diabetes Care 2004, 27:1794-1797.
147. Kuhn F, Barker D Intravitreal injection of triamcinolone acetonide for diabetic macular edema. Arch Ophthalmol 2004, 122:1082-1083. author reply 6-8.
148. Massin P, Audren F, Haouchine B, et al. Intravitreal triamcinolone acetonide for diabetic diffuse macular edema: preliminary results of a prospective controlled trial. Ophthalmology 2004, 111:218-224. discussion 24-5.
149. Rodriguez-Coleman H, Yuan P, Kim H, et al. Intravitreal injection of triamcinolone for diffuse macular edema. Arch Ophthalmol 2004, 122:1085-1086. author reply 6-8.
150. Wong R, Sherefat H, Bartholomew D, et al. Intravitreal injection of triamcinolone for diffuse diabetic macular edema. Arch Ophthalmol 2004, 122:1082. author reply 6-8.
151. Diabetic Retinopathy Clinical Research Network A randomized trial comparing intravitreal triamcinolone acetonide and focal/grid photocoagulation for diabetic macular edema. Ophthalmology 2008, 115:1447-1449. 9 e1-10.
152. Beck RW, Edwards AR, Aiello LP, et al. Three-year follow-up of a randomized trial comparing focal/grid photocoagulation and intravitreal triamcinolone for diabetic macular edema. Arch Ophthalmol 2009, 127:245-251.
153. Elman MJ, Aiello LP, Beck RW, et al. Randomized trial evaluating ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 2010, 117:1064-1077.
154. Early Treatment Diabetic Retinopathy Study design and baseline patient characteristics. ETDRS report number 7. Ophthalmology 1991, 98:741-756.
155. Treatment techniques and clinical guidelines for photocoagulation of diabetic macular edema. Early Treatment Diabetic Retinopathy Study Report Number 2. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology 1987, 94:761-774.
156. Diabetic Retinopathy Clinical Research Network [Internet] [cited 2012 Feb 20. Modified-ETDRS focal photocoagulation technique. Available from. http://publicfiles.jaeb.org/drcrnet/Misc/FocalGridProcedure42711.pdf.
157. Akduman L, Olk RJ Diode laser (810 nm) versus argon green (514 nm) modified grid photocoagulation for diffuse diabetic macular edema. Ophthalmology 1997, 104:1433-1441.
158. Bolz M, Kriechbaum K, Simader C, et al. In vivo retinal morphology after grid laser treatment in diabetic macular edema. Ophthalmology 2010, 117:538-544.
159. Kumar V, Ghosh B, Mehta DK, et al. Functional outcome of subthreshold versus threshold diode laser photocoagulation in diabetic macular oedema. Eye (Lond) 2010, 24:1459-1465.
160. Lavinsky D, Cardillo JA, Melo LA, et al. Randomized clinical trial evaluating mETDRS versus normal or high-density micropulse photocoagulation for diabetic macular edema. Invest Ophthalmol Vis Sci 2011, 52:4314-4323.
161. Muqit MM, Gray JC, Marcellino GR, et al. Barely visible 10-millisecond pascal laser photocoagulation for diabetic macular edema: observations of clinical effect and burn localization. Am J Ophthalmol 2010, 149:979-986. e2.
162. Nakamura Y, Mitamura Y, Ogata K, et al. Functional and morphological changes of macula after subthreshold micropulse diode laser photocoagulation for diabetic macular oedema. Eye (Lond) 2010, 24:784-788.
163. Ohkoshi K, Yamaguchi T Subthreshold micropulse diode laser photocoagulation for diabetic macular edema in Japanese patients. Am J Ophthalmol 2010, 149:133-139.
164. Venkatesh P, Ramanjulu R, Azad R, et al. Subthreshold micropulse diode laser and double frequency neodymium: YAG laser in treatment of diabetic macular edema: a prospective, randomized study using multifocal electroretinography. Photomed Laser Surg 2011.
165. Figueira J, Khan J, Nunes S, et al. Prospective randomised controlled trial comparing sub-threshold micropulse diode laser photocoagulation and conventional green laser for clinically significant diabetic macular oedema. Br J Ophthalmol 2009, 93:1341-1344.
166. Jain A, Collen J, Kaines A, et al. Short-duration focal pattern grid macular photocoagulation for diabetic macular edema: four-month outcomes. Retina 2010, 30:1622-1626.
167. Luttrull JK, Musch DC, Mainster MA Subthreshold diode micropulse photocoagulation for the treatment of clinically significant diabetic macular oedema. Br J Ophthalmol 2005, 89:74-80.
168. Fong DS, Strauber SF, Aiello LP, et al. Comparison of the modified Early Treatment Diabetic Retinopathy Study and mild macular grid laser photocoagulation strategies for diabetic macular edema. Arch Ophthalmol 2007, 125:469-480.
169. Elman MJ, Bressler NM, Qin H, et al. Expanded 2-year follow-up of ranibizumab plus prompt or deferred laser or triamcinolone plus prompt laser for diabetic macular edema. Ophthalmology 2011, 118:609-614.
170. Hofman P, Blaauwgeers HG, Tolentino MJ, et al. VEGF-A induced hyperpermeability of blood-retinal barrier endothelium in vivo is predominantly associated with pinocytotic vesicular transport and not with formation of fenestrations. Vascular endothelial growth factor-A. Curr Eye Res 2000, 21:637-645.
171. Michels S, Rosenfeld PJ, Puliafito CA, et al. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration twelve-week results of an uncontrolled open-label clinical study. Ophthalmology 2005, 112:1035-1047.
172. Moshfeghi AA, Rosenfeld PJ, Puliafito CA, et al. Systemic bevacizumab (Avastin) therapy for neovascular age-related macular degeneration: twenty-four-week results of an uncontrolled open-label clinical study. Ophthalmology 2006, 113:2002 e1-12.
173. Nguyen QD, Shah SM, Hafiz G, et al. A phase I trial of an IV-administered vascular endothelial growth factor trap for treatment in patients with choroidal neovascularization due to age-related macular degeneration. Ophthalmology 2006, 113:1522.e1-1522.e14.
174. Cunningham ET, Adamis AP, Altaweel M, et al. A phase II randomized double-masked trial of pegaptanib, an anti-vascular endothelial growth factor aptamer, for diabetic macular edema. Ophthalmology 2005, 112:1747-1757.
175. Faghihi H, Roohipoor R, Mohammadi SF, et al. Intravitreal bevacizumab versus combined bevacizumab-triamcinolone versus macular laser photocoagulation in diabetic macular edema. Eur J Ophthalmol 2008, 18:941-948.
176. Lam DS, Lai TY, Lee VY, et al. Efficacy of 1.25 MG versus 2.5 MG intravitreal bevacizumab for diabetic macular edema: six-month results of a randomized controlled trial. Retina 2009, 29:292-299.
177. Nguyen QD, Shah SM, Heier JS, et al. Primary end point (six months) results of the Ranibizumab for Edema of the mAcula in diabetes (READ-2) study. Ophthalmology 2009, 116:2175-2181.
178. Paccola L, Costa RA, Folgosa MS, et al. Intravitreal triamcinolone versus bevacizumab for treatment of refractory diabetic macular oedema (IBEME study). Br J Ophthalmol 2008, 92:76-80.
179. Scott IU, Edwards AR, Beck RW, et al. A phase II randomized clinical trial of intravitreal bevacizumab for diabetic macular edema. Ophthalmology 2007, 114:1860-1867.
180. Soheilian M, Ramezani A, Obudi A, et al. Randomized trial of intravitreal bevacizumab alone or combined with triamcinolone versus macular photocoagulation in diabetic macular edema. Ophthalmology 2009, 116:1142-1150.
181. Massin P, Bandello F, Garweg JG, et al. Safety and efficacy of ranibizumab in diabetic macular edema (RESOLVE Study): a 12-month, randomized, controlled, double-masked, multicenter phase II study. Diabetes Care 2010, 33:2399-2405.
182. Mitchell P, Bandello F, Schmidt-Erfurth U, et al. The RESTORE study: ranibizumab monotherapy or combined with laser versus laser monotherapy for diabetic macular edema. Ophthalmology 2011, 118:615-625.
183. Michaelides M, Kaines A, Hamilton RD, et al. A prospective randomized trial of intravitreal bevacizumab or laser therapy in the management of diabetic macular edema (BOLT study) 12-month data: report 2. Ophthalmology 2010, 117:1078-1086.
184. Crum R, Szabo S, Folkman J A new class of steroids inhibits angiogenesis in the presence of heparin or a heparin fragment. Science 1985, 230:1375-1378.
185. Folkman J, Ingber DE Angiostatic steroids. Method of discovery and mechanism of action. Ann Surg 1987, 206:374-383.
186. Gordon DM Prednisone and prednisolone in ocular disease. Am J Ophthalmol 1956, 41:593-600.
187. Ingber DE, Madri JA, Folkman J A possible mechanism for inhibition of angiogenesis by angiostatic steroids: induction of capillary basement membrane dissolution. Endocrinology 1986, 119:1768-1775.
188. Fauci A Clinical aspects of immunosuppression: use of cytotoxic agents and corticosteroids. Immunology II 1978, WB Saunders, Philadelphia. J.A. Bellanti (Ed.).
189. Nussenblatt R, Whitcup S, Palestine A Uveitis: fundamentals and clinical practice 1996, Mosby, St Louis.
190. Callanan DG, Jaffe GJ, Martin DF, et al. Treatment of posterior uveitis with a fluocinolone acetonide implant: three-year clinical trial results. Arch Ophthalmol 2008, 126:1191-1201.
191. Pavesio C, Zierhut M, Bairi K, et al. Evaluation of an intravitreal fluocinolone acetonide implant versus standard systemic therapy in noninfectious posterior uveitis. Ophthalmology 2010, 117:567-575. 75 e1.
192. The effect of ruboxistaurin on visual loss in patients with moderately severe to very severe nonproliferative diabetic retinopathy: initial results of the Protein Kinase C beta Inhibitor Diabetic Retinopathy Study (PKC-DRS) multicenter randomized clinical trial. Diabetes 2005, 54:2188-2197.
193. Jaffe GJ, Martin D, Callanan D, et al. Fluocinolone acetonide implant (Retisert) for noninfectious posterior uveitis: thirty-four-week results of a multicenter randomized clinical study. Ophthalmology 2006, 113:1020-1027.
194. Schwartz SG, Flynn HW Fluocinolone acetonide implantable device for diabetic retinopathy. Curr Pharm Biotechnol 2011, 12:347-351.
195. Campochiaro PA, Brown DM, Pearson A, et al. Long-term benefit of sustained-delivery fluocinolone acetonide vitreous inserts for diabetic macular edema. Ophthalmology 2011, 118:626-635.
196. Haller JA, Kuppermann BD, Blumenkranz MS, et al. Randomized controlled trial of an intravitreous dexamethasone drug delivery system in patients with diabetic macular edema. Arch Ophthalmol 2010, 128:289-296.
197. Harbour JW, Smiddy WE, Flynn HW, et al. Vitrectomy for diabetic macular edema associated with a thickened and taut posterior hyaloid membrane. Am J Ophthalmol 1996, 121:405-413.
198. Kaiser PK, Riemann CD, Sears JE, et al. Macular traction detachment and diabetic macular edema associated with posterior hyaloidal traction. Am J Ophthalmol 2001, 131:44-49.
199. Lewis H, Abrams GW, Blumenkranz MS, et al. Vitrectomy for diabetic macular traction and edema associated with posterior hyaloidal traction. Ophthalmology 1992, 99:753-759.
200. Pendergast SD, Hassan TS, Williams GA, et al. Vitrectomy for diffuse diabetic macular edema associated with a taut premacular posterior hyaloid. Am J Ophthalmol 2000, 130:178-186.
201. Haller JA, Qin H, Apte RS, et al. Vitrectomy outcomes in eyes with diabetic macular edema and vitreomacular traction. Ophthalmology 2010, 117:1087-1093.
202. Dillinger P, Mester U Vitrectomy with removal of the internal limiting membrane in chronic diabetic macular oedema. Graefes Arch Clin Exp Ophthalmol 2004, 242:630-637.
203. Figueroa MS, Contreras I, Noval S Surgical and anatomical outcomes of pars plana vitrectomy for diffuse nontractional diabetic macular edema. Retina 2008, 28:420-426.
204. Hartley KL, Smiddy WE, Flynn HW, et al. Pars plana vitrectomy with internal limiting membrane peeling for diabetic macular edema. Retina 2008, 28:410-419.
205. Higuchi A, Ogata N, Jo N, et al. Pars plana vitrectomy with removal of posterior hyaloid face in treatment of refractory diabetic macular edema resistant to triamcinolone acetonide. Jpn J Ophthalmol 2006, 50:529-531.
206. Ikeda T, Sato K, Katano T, et al. Vitrectomy for cystoid macular oedema with attached posterior hyaloid membrane in patients with diabetes. Br J Ophthalmol 1999, 83:12-14.
207. La Heij EC, Hendrikse F, Kessels AG, et al. Vitrectomy results in diabetic macular oedema without evident vitreomacular traction. Graefes Arch Clin Exp Ophthalmol 2001, 239:264-270.
208. Recchia FM, Ruby AJ, Carvalho Recchia CA Pars plana vitrectomy with removal of the internal limiting membrane in the treatment of persistent diabetic macular edema. Am J Ophthalmol 2005, 139:447-454.
209. Rosenblatt BJ, Shah GK, Sharma S, et al. Pars plana vitrectomy with internal limiting membranectomy for refractory diabetic macular edema without a taut posterior hyaloid. Graefes Arch Clin Exp Ophthalmol 2005, 243:20-25.
210. Yanyali A, Horozoglu F, Celik E, et al. Long-term outcomes of pars plana vitrectomy with internal limiting membrane removal in diabetic macular edema. Retina 2007, 27:557-566.
211. Patel JI, Hykin PG, Schadt M, et al. Diabetic macular oedema: pilot randomised trial of pars plana vitrectomy vs macular argon photocoagulation. Eye (Lond) 2006, 20:873-881.
212. Thomas D, Bunce C, Moorman C, et al. A randomised controlled feasibility trial of vitrectomy versus laser for diabetic macular oedema. Br J Ophthalmol 2005, 89:81-86.
213. The Diabetic Retinopathy Study Research Group Photocoagulation treatment of proliferative diabetic retinopathy. Clinical application of Diabetic Retinopathy Study (DRS) findings, DRS Report Number 8. Ophthalmology 1981, 88:583-600.
214. Bressler NM, Edwards AR, Beck RW, et al. Exploratory analysis of diabetic retinopathy progression through 3 years in a randomized clinical trial that compares intravitreal triamcinolone acetonide with focal/grid photocoagulation. Arch Ophthalmol 2009, 127:1566-1571.
215. The DAMAD Study Group Effect of aspirin alone and aspirin plus dipyridamole in early diabetic retinopathy. A multicenter randomized controlled clinical trial. Diabetes 1989, 38:491-498.
216. The TIMAD Study Group Ticlopidine treatment reduces the progression of nonproliferative diabetic retinopathy. Arch Ophthalmol 1990, 108:1577-1583.
217. Effects of aspirin treatment on diabetic retinopathy. ETDRS report number 8. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology 1991, 98:757-765.
218. Chew EY, Klein ML, Murphy RP, et al. Effects of aspirin on vitreous/preretinal hemorrhage in patients with diabetes mellitus. Early Treatment Diabetic Retinopathy Study report no. 20. Arch Ophthalmol 1995, 113:52-55.
219. Sorbinil Retinopathy Trial Research Group A randomized trial of sorbinil, an aldose reductase inhibitor, in diabetic retinopathy. Arch Ophthalmol 1990, 108:1234-1244.
220. Aiello LP, Bursell SE, Clermont A, et al. Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective beta-isoform-selective inhibitor. Diabetes 1997, 46:1473-1480.
221. Xu X, Zhu Q, Xia X, et al. Blood-retinal barrier breakdown induced by activation of protein kinase C via vascular endothelial growth factor in streptozotocin-induced diabetic rats. Curr Eye Res 2004, 28:251-256.
222. Yokota T, Ma RC, Park JY, et al. Role of protein kinase C on the expression of platelet-derived growth factor and endothelin-1 in the retina of diabetic rats and cultured retinal capillary pericytes. Diabetes 2003, 52:838-845.
223. Zhu Q, Xu X, Xia X, et al. Role of protein kinase C on the alteration of retinal endothelin-1 in streptozotocin-induced diabetic rats. Exp Eye Res 2005, 81:200-206.
224. PKC-DRS Study Group The effect of ruboxistaurin on visual loss in patients with moderately severe to very severe nonproliferative diabetic retinopathy: initial results of the Protein Kinase C beta Inhibitor Diabetic Retinopathy Study (PKC-DRS) multicenter randomized clinical trial. Diabetes 2005, 54:2188-2197.
225. Aiello LP, Davis MD, Girach A, et al. Effect of ruboxistaurin on visual loss in patients with diabetic retinopathy. Ophthalmology 2006, 113:2221-2230.
226. Congdon N, O'Colmain B, Klaver CC, et al. Causes and prevalence of visual impairment among adults in the United States. Arch Ophthalmol 2004, 122:477-485.
227. World Health Organization [Internet] Geneva: WHO; 2011 August [cited 2012 2 Feb]. Fact sheet no. 312: Diabetes. Available from. http://www.who.int/mediacentre/factsheets/fs312/en/.
228. Centers for Disease Control and Prevention [Press release on the Internet] CDC: Atlanta, GA, Oct [cited 2012 Feb 2]. Number of Americans with diabetes projected to double or triple by 2050. Available from. http://www.cdc.gov/media/pressrel/2010/r101022.html.